Practice patterns of SGO members for stage IIIA endometrial cancer

2005 ◽  
Vol 98 (1) ◽  
pp. 77-83 ◽  
Author(s):  
Christine M. Lee ◽  
Brian M. Slomovitz ◽  
Marilyn Greer ◽  
Sheena Sharma ◽  
Mary Ann Gregurich ◽  
...  
2015 ◽  
Vol 137 ◽  
pp. 150
Author(s):  
E.B. Pereira ◽  
B. De ◽  
V. Kolev ◽  
K. Zakashansky ◽  
S. Green ◽  
...  

2020 ◽  
Vol 27 (2) ◽  
pp. 482-488 ◽  
Author(s):  
Malte Renz ◽  
Elisabeth Diver ◽  
Diana English ◽  
Elizabeth Kidd ◽  
Oliver Dorigo ◽  
...  

2011 ◽  
Vol 2011 ◽  
pp. 1-7 ◽  
Author(s):  
Jan J. Jobsen ◽  
Lambert Naudin ten Cate ◽  
Marnix L. M. Lybeert ◽  
Astrid Scholten ◽  
Elzbieta M. van der Steen-Banasik ◽  
...  

Objective. The aim of this study is to look at possible differences in outcome between serosa and adnexal involvement stage IIIA endometrial carcinoma.Methods. 67 patients with stage IIIA endometrial carcinoma were included, 46 with adnexal involvement and 21 with serosa. A central histopathological review was performed.Results. The 7-year locoregional failure rate was (LRFR) 2.2% for adnexal involvement and 16.0% for involvement of the serosa (P=.0522). The 7-year distant metastasis-free survival was 72.7% for adnexal involvement and 58.7% for serosa (P=.3994). The 7-year disease-specific survival (DSS) was 71.8% for patients with adnexal involvement and 75.4% for patients with serosa.Conclusion. Endometrial carcinoma stage IIIA with involvement of the adnexa or serosa showed to have a comparable disease-specific survival. Locoregional control was worse for serosa involvement compared to adnexa.


2006 ◽  
Vol 16 (3) ◽  
pp. 1370-1373 ◽  
Author(s):  
E. Jewell ◽  
A. A. Secord ◽  
T. Brotherton ◽  
A. Berchuck

Systemic therapy of metastatic endometrial cancer is relatively ineffective. Response rates to chemotherapy and hormonal therapy in published studies range from 11% to 57%, but most responses are partial and of limited duration. In this case, we present a 76-year-old woman with stage IIIA endometrial adenocarcinoma who was initially treated with surgery and pelvic radiation. She developed multiple pulmonary metastases. She was treated with weekly paclitaxel chemotherapy. Immunostaining revealed that the primary endometrial cancer overexpressed HER-2/neu. Trastuzumab was added to the regimen, and a dramatic partial response was achieved. After a second pulmonary relapse following discontinuation of prior therapy, she was again successfully treated with trastuzumab in combination with paclitaxel and then docetaxel. Therefore, trastuzumab may be a useful adjuvant to taxane-based chemotherapy in some patients with metastatic endometrial cancers that overexpress HER-2/neu.


Author(s):  
Jessica Jou ◽  
Lindsey Charo ◽  
Marianne Hom-Tedla ◽  
Katherine Coakley ◽  
Pratibha Binder ◽  
...  

2007 ◽  
Vol 104 (2) ◽  
pp. 401-405 ◽  
Author(s):  
Laura J. Havrilesky ◽  
Janiel M. Cragun ◽  
Brian Calingaert ◽  
Angeles Alvarez Secord ◽  
Fidel A. Valea ◽  
...  

2015 ◽  
Vol 38 (3) ◽  
pp. 283-288 ◽  
Author(s):  
Marija M. Lum ◽  
Thomas W. Belnap ◽  
Jonathan Frandsen ◽  
Aaron P. Brown ◽  
William T. Sause ◽  
...  

2016 ◽  
Vol 26 (2) ◽  
pp. 341-347 ◽  
Author(s):  
Elena B. Pereira ◽  
Brian De ◽  
Valentin Kolev ◽  
Konstantin Zakashansky ◽  
Sheryl Green ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document